Zepbound and Wegovy: Analyzing the Landscape of GLP-1 Drug Utilization
Recent findings indicate that 57.4 million adults under 65 could be eligible for GLP-1 medications based on FDA indications. This includes a staggering 36.2 million diagnosed with obesity. Despite this potential, KFF analysis reports that only 6% of adults are currently utilizing GLP-1 drugs.
Cost Implications and Coverage
GLP-1 drugs like Zepbound cost around $1,059.87, while Wegovy is slightly more expensive. The financial impact could surge for health plans if utilization rises significantly.
Emerging Approvals and Future Directions
Wegovy's recent approval for reducing cardiovascular risks may enhance coverage options, particularly for Medicare beneficiaries. Simultaneously, ongoing studies indicate that Zepbound shows promise in alleviating sleep apnea severity in those with obesity.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.